This week, Ensera Design celebrates a major milestone in medical innovation with the announcement of the Neupulse device. For the last four years, we have worked in close partnership with the team at Neupulse to develop a transformative wearable product that helps people with Tourette Syndrome gain control over their tics.
“ Ensera design have been a critical partner for Neupulse in developing the Neupulse device, vital to the relationship is a shared understanding and vision of changing the lives of people living with Tourette Syndrome”
Paul Cable, CEO, Neurotherapeutics Ltd.
The project began by taking pioneering neuroscientific research from the University of Nottingham and translating it into a functional medical device. The result is a discreet, wrist-worn device that provides gentle, rhythmic electrical stimulation of the median nerve. This stimulation targets the specific brain networks that cause tics, offering significant relief from both tic frequency and the urge to tic, as demonstrated in clinical trials.
Since 2021, our product development journey has been deeply collaborative. We assisted Neurotherapeutics with the design and development of trial devices needed for clinical trials, which were instrumental in proving the therapy’s effectiveness. With these hugely positive trial results, our focus shifted to developing the device for commercial availability.
We have worked to enhance the device’s size, comfort, usability, and overall functionality, ensuring it seamlessly integrates into the daily lives of users.
As Emma McNally, CEO of UK charity Tourettes Action, notes:
“This wearable and self-managing treatment could change the lives of people living with Tourette’s. It potentially offers a flexible and accessible option for the many people who are currently struggling to access treatment.”
The timing of this announcement aligns with a wider push for Tourette’s awareness, notably with the release of the film I Swear, which follows the life of campaigner John Davidson MBE. This increased public understanding, combined with the availability of effective new therapies like Neupulse, signals a brighter future for those living with the condition. The Neupulse device is expected to be available in mid 2026, following the successful completion of the Medical device regulatory approval process.
“It is rare that the opportunity to work with such groundbreaking scientific innovation comes along,” said Craig Wightman, Ensera Design’s Chief Design Officer. “Ever since we were introduced to the project, we have felt a sense of duty to help bring this game-changing product to life”.
Read the full case study here: Neurotherapeutics – Neupulse | Ensera Design | Healthcare-Focused Design Consultancy
Image source: www.iswearfilm.com
October 14th, 2025
Our new trading name reflects our expanded design expertise, international footprint, and capability in design to manufacturing as part of the wider Ensera Group.
June 13th, 2025
We are thrilled to announce that our UK studio has been awarded a prestigious EcoVadis Gold rating, placing us in the top 5% of companies...
June 25th, 2024
Partnering with William Oak Diagnostics to reduce the environmental impact of their innovative micronutrient testing device.
View more:
All NewsWhether you’re looking to identify your next innovation priority, or keen to accelerate development of an existing concept, we can help you move forward with momentum.
